Xenon Pharmaceuticals Inc. (XENE)
NasdaqGM · USD · Healthcare · Biotechnology
$36.01 (+0.67%) as of
Key statistics
- Market cap
- 3.49B
- Forward P/E
- -7.62
- EPS (TTM)
- -4.74
- Dividend yield
- 0.00%
- 52-week range
- 33.38 – 72.66
- Beta
- 0.60
- Profit margin
- 0.00%
- Analyst target
- $71.94
- Volume
- 1.08M
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Burnaby, BC, Canada
- Employees
- 358
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.